FGF19-treated CKD mice clearly presented a substantial rightward shift in the distribution of myofiber sizes (Fig. 2B, E–F), with a trend of increased cross‐sectional area average in tibialis anterior myofibers (1206 ± 57.91 vs 1083 ± 33.58 μm2 in CKD mice, p = 0.07) (Fig. 2C). Here, FGF19 is linked to chronic kidney disease.